Diabetes management with Biosimilar Insulin- Glargine

Speciality: Endocrinology


Speaker:

Dr. Sunil Gupta | MD, FACE (USA), FRCP (London, Glasgow & Edinburgh), FACP (USA), FICP, FIAMS, FIACM, FDI, FRSSDI, Diabetologist

Dr. Anil Bhansali | Medical Director at Gini Health, Endocrinologist, Professor and erstwhile Head, Department of Endocrinology at PGIMER Chandigarh.

Description:

A warm welcome to all the medical practitioners in this interesting session of biosimilar insulin Glargine which is a product of Biocon.

Insulin is a hormone secreted from pancreas that helps blood sugar to enter the body's cells so it can be used for energy. Insulin also signals the liver to store blood sugar for later use. It is one of the important components that helps in controlling diabetes in patients.

The speakers Dr. Sunil Gupta, Dr. Anil Bhansali and panel has provided an elaborative knowledge on biosimilar insulin Glargine in the management of diabetes in patients. 

Biosimilar insulins are manufactured in living organisms (e.g., yeast and bacteria) to produce large quantities of the product, which limits the ability to manufacture exact replicas of original biological medications. Insulin glargine is a synthetic version of human insulin that is FDA approved to treat adults and children. It is long-acting with the ability to control sugar all day long.

Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
 


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer during young adulthood carries long-term mental toll, study finds

2.

In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.

3.

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

4.

Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.

5.

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot